

PRODUCT MONOGRAPH

^{Pr}**TORISEL™**

Temsirolimus

Concentrate for Injection

25mg/mL

mTOR kinase inhibitor – Antineoplastic Agent

T.M. Wyeth Canada
Pfizer Canada ULC, Licensee
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5

Pfizer Canada ULC.

Date of Revision:
21 December 2016

L4-Notification 10 May 2021

Submission Control Number: 199380

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	11
DRUG INTERACTIONS.....	16
DOSAGE AND ADMINISTRATION.....	18
OVERDOSAGE	21
ACTION AND CLINICAL PHARMACOLOGY	21
STORAGE AND STABILITY.....	26
SPECIAL HANDLING INSTRUCTIONS	26
DOSAGE FORMS, COMPOSITION AND PACKAGING	26
PART II: SCIENTIFIC INFORMATION.....	28
PHARMACEUTICAL INFORMATION.....	28
CLINICAL TRIALS.....	29
DETAILED PHARMACOLOGY	33
TOXICOLOGY	35
REFERENCES	44
PART III: CONSUMER INFORMATION.....	45

PrTORISEL™

(Temsirolimus Concentrate for Injection)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous Infusion	Concentrate for Injection 25 mg/mL	Dehydrated alcohol
	Diluent	Dehydrated alcohol <i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING SECTION.</i>

INDICATIONS AND CLINICAL USE

TORISEL (temsirolimus concentrate for injection) is indicated for the treatment of metastatic renal cell carcinoma.

Geriatrics (≥ 65 years of age):

No specific overall differences in safety were observed between patients younger than 65 or older than 65 (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics).

Overall survival in a subset of patients 65 years of age or older (N=64) treated with TORISEL was shorter than that observed with patients under 65 years of age (see CLINICAL TRIALS). The clinical relevance of this subgroup analysis is unclear.

No specific dose adjustment is recommended for elderly patients.

Pediatrics:

There is no indication for the use of TORISEL in the pediatric population. The effectiveness of TORISEL in 71 pediatric patients (aged 1 year to 21 years) with advanced relapsed/refractory solid tumors was not established (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).

CONTRAINDICATIONS

TORISEL (temsirolimus concentrate for injection) is contraindicated in patients who have a history of anaphylaxis after exposure to temsirolimus, sirolimus or any other component of TORISEL (see DOSAGE FORMS, COMPOSITION AND PACKAGING).

TORISEL is contraindicated in patients with bilirubin >1.5 x ULN (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

TORISEL should be prescribed by a qualified healthcare professional who is experienced in the management of metastatic renal cell carcinoma. TORISEL should be administered in an appropriate setting, under the supervision of a qualified healthcare professional. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.

The following are clinically significant adverse events:

- Hypersensitivity/Infusion reactions (see “Sensitivity/Resistance” section below)
- Hyperglycemia / Glucose Intolerance (see “Endocrine and Metabolism” section below)
- Infections (see “Immune - Infections” section below)
- Interstitial Lung Disease (see “Respiratory” section below)
- Renal Failure (see “Renal Dysfunction” section below)

Bleeding

Patients with central nervous system tumors (primary CNS tumors or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes) while receiving therapy with temsirolimus

Bleeding events were noted in 103 (25%) of patients receiving temsirolimus. Epistaxis was the commonest bleeding event with 3-times the incidence in the temsirolimus arm than in the IFN arm (12.0% in the temsirolimus arm and 3.5% in the IFN arm). Most bleeding events were grade 1 or 2, with only 13 (3%) grade 3 and 4.

Carcinogenesis and Mutagenesis

Carcinogenicity studies have not been conducted with temsirolimus. However, sirolimus, the major metabolite of temsirolimus in humans, induced malignant lymphoma, hepatocellular adenoma and carcinoma, and testicular adenoma in mice and/or rats. Patients receiving immunosuppression regimens involving combinations of drugs, including sirolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin.

Cardiovascular

TORISEL is associated with small (< 10 msec) but statistically significant QT/QTc interval prolongation (see ACTION AND CLINICAL PHARMACOLOGY/Cardiac Electrophysiology).

Hypertension has been reported in 14 patients (7%) receiving TORISEL compared with 8 patients (4%) receiving Interferon in the Renal Cell Carcinoma Study (3066K1-304-WW). In Study 3066K1-155-US, diastolic and systolic blood pressures of subjects continued to steadily increase up to 48 hours after administration of Temsirolimus (see ADVERSE REACTIONS).

Drug-Drug Interactions

Agents Inducing CYP3A Metabolism

Agents such as carbamazepine, phenytoin, barbiturates, rifabutin, rifampicin, and St John's Wort are strong inducers of CYP3A4/5 and may decrease composite exposures of the active moieties, temsirolimus and its metabolite, sirolimus. Therefore, concomitant treatment with agents that have CYP3A4/5 induction potential should be avoided. The safety profile of temsirolimus at doses greater than 25 mg in the presence of a CYP3A4/5 inducer has not been evaluated in the context of compensation for the reduced sirolimus exposure (see OVERDOSAGE).

Agents Inhibiting CYP3A Metabolism

Agents such as protease inhibitors, anti-fungals, macrolide antibiotics, nefazodone, and selective serotonin inhibitors are strong CYP3A4 inhibitors and may increase blood concentrations of the active moieties, temsirolimus and its metabolite, sirolimus. Therefore, concomitant treatment with agents that have CYP3A4 inhibition potential should be avoided. Alternative treatments with agents that do not have CYP3A4 inhibition potential should be considered (see DRUG INTERACTIONS).

Pharmacodynamic Drug Interactions

TORISEL in combination with sunitinib, gemcitabine or 5-fluorouracil has been associated with serious adverse drug reactions. Fatal events have been seen when TORISEL was combined with 5-fluorouracil.

Angioneurotic edema-type reactions (including delayed reactions occurring two months following initiation of therapy) have been observed in some patients who received TORISEL and angiotensin-converting enzyme (ACE) and/or calcium channel blocker (e.g., amlodipine) inhibitors concomitantly (see DRUG INTERACTIONS).

Endocrine and Metabolism

Hyperglycemia/Glucose Intolerance

The use of TORISEL in renal cell carcinoma (RCC) patients was frequently associated with increases in serum glucose. In Study 1, hyperglycemia was present on at least one occasion in

over 82% of patients receiving temsirolimus and was an adverse event (greater than 13.9 mmol/L) in 15.9% of patients. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.

Hyperlipidemia

The use of TORISEL in RCC patients was frequently associated with increases in serum triglycerides and cholesterol. In Study 1, hypercholesterolemia was present on at least one occasion in 80% of patients receiving temsirolimus, and hypertriglyceridemia was present in over 83% of patients. One or both dyslipidemias was an adverse event (cholesterol greater than 10.34 mmol/L, triglycerides greater than 5x upper limit of normal) in 45.2% of patients. This may require initiation, or increase in the dose of lipid-lowering agents. Serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.

Gastrointestinal

Cases of bowel perforation (including fatal outcomes) have occurred in patients who received TORISEL (see ADVERSE REACTIONS).

Stomatitis and mucositis were significantly more common in the temsirolimus arm, with combined incidences of 19 (10%) and 86 (41%) in the IFN and temsirolimus arms, respectively. Grade 3 or 4 stomatitis and mucositis was reported in 0 and 6 (3%) in each arm, respectively.

Hematological

Anemia was very common across the treatment arms, with over 90% of patients reporting at least one low hemoglobin level. Grade 3 and 4 anemia was reported in 43 (21.5%) and 41 (19.7%) in the IFN and temsirolimus arms, respectively. Transfusion of at least one unit of blood was given to 51 (25.5%) and 63 (30.3%) patients in each arm respectively.

Leukopenia, neutropenia, lymphopenia and thrombocytopenia including grade 3 and 4 events were commonly reported in all treatment arms (see Table 2).

Immune

Infections

Infection related events were reported in patients receiving temsirolimus more than twice as frequently than in those receiving IFN only (31% vs. 15%). Temsirolimus may be immunosuppressive. Patients should be carefully observed for the occurrence of infections, including opportunistic infections (see ADVERSE REACTIONS). Cases of *Pneumocystis jiroveci* pneumonia (PJP), some with fatal outcomes, have been reported in patients who received temsirolimus, many of whom also received corticosteroids or other immunosuppressive

agents. In some cases, prophylaxis of PJP may be considered, although there are no prospective clinical trial data to support this.

Sepsis

Cases of sepsis (including septic shock) have been reported in patients treated with TORISEL.

Vaccinations

The use of live vaccines and close contact with people who have received live vaccines should be avoided during treatment with temsirolimus. Examples of live vaccines are: measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.

Musculoskeletal and Connective Tissue Disorders

Myalgia, arthralgia, and increased serum creatine phosphokinase have been observed in subjects treated with TORISEL.

Peri-Operative Considerations

Wound Healing Complications

The use of TORISEL has been associated with abnormal wound healing. Therefore, caution should be exercised with the use of TORISEL in the peri-surgical period.

Renal Dysfunction

Renal insufficiency was a common treatment emergent adverse event. In study 1, elevated creatinine was present on at least one occasion in 57.2% of patients receiving temsirolimus and in 48.5% of patients receiving IFN. Increased creatinine was an adverse event (greater than 3x upper limit of normal) in 3.4% of patients receiving temsirolimus and 1% of patients receiving IFN.

Cases of rapidly progressive and sometimes fatal acute renal failure not clearly related to disease progression occurred in patients who received TORISEL.

Effect of renal impairment on TORISEL pharmacokinetics has not been studied.

Hepatic Dysfunction

Dose de-escalation and multiple dose interruption were observed in patients with mild hepatic impairment primarily due to thrombocytopenia.

TORISEL was evaluated in a dose escalation phase 1 study in 110 patients with advanced malignancies and either normal or impaired hepatic function. Patients with moderate and severe hepatic impairment (bilirubin >1.5 X ULN) had increased rates of adverse events and deaths, including deaths due to progression of underlying cancer, during the study.

TORISEL is contraindicated in patients with bilirubin $>1.5 \times \text{ULN}$ due to increased risk of death, including deaths due to progression of underlying cancer (see CONTRAINDICATIONS).

Use caution when treating patients with mild hepatic impairment. Concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated AST or bilirubin levels. For patients with mild hepatic impairment (bilirubin $>1-1.5 \times \text{ULN}$ or AST $>\text{ULN}$ but bilirubin $\leq \text{ULN}$), a reduction of the temsirolimus dose to 15 mg/week could be considered. Assessment of AST and bilirubin levels is recommended before initiation of temsirolimus and periodically thereafter (see ACTION AND CLINICAL PHARMACOLOGY).

Respiratory

Interstitial Lung Disease

Cases of interstitial lung disease, including some fatalities, have occurred in patients who received TORISEL. Some patients were asymptomatic with infiltrates, including ground glass opacities and consolidation, detected on CT scan or chest X-ray. Others presented with symptoms such as dyspnea, cough, hypoxia, and fever. In a series of patients receiving intravenous temsirolimus 25 mg weekly for advanced neuroendocrine tumours or advanced endometrial carcinoma, 8 out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic¹. Some patients required discontinuation of TORISEL or treatment with corticosteroids and/or antibiotics, while some patients continued treatment without additional intervention.

It is recommended that patients undergo baseline radiographic assessment by lung computed tomography scan or chest radiograph prior to the initiation of temsirolimus therapy. Follow such assessments periodically, even in the absence of clinical respiratory symptoms.

It is recommended that patients be followed closely for occurrence of clinical respiratory symptoms. If clinically significant respiratory symptoms develop, consider withholding temsirolimus administration until after recovery of symptoms and improvement of radiographic findings related to Pneumonitis. Opportunistic infections such as *Pneumocystis jiroveci* pneumonia (PJP) should be considered in the differential diagnosis. Empiric treatment with corticosteroids and/or antibiotics may be considered. For patients who require use of corticosteroids, prophylaxis of PJP may be considered, although there are no prospective clinical trial data to support this.

Sensitivity/Resistance

Hypersensitivity/Infusion Reactions

Hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions), including but not limited to flushing, chest pain, dyspnea, hypotension, apnea, loss of consciousness, hypersensitivity and anaphylaxis, have been associated with the administration of TORISEL. These reactions can occur very early in the first infusion, but may also occur with

subsequent infusions. Patients should be monitored early during the infusion and appropriate supportive care should be available. TORISEL infusion should be interrupted in all patients with severe infusion reactions and appropriate medical therapy administered. A benefit-risk assessment should be done prior to the continuation of TORISEL therapy in patients with severe or life-threatening reactions.

Sirolimus is the major metabolite of temsirolimus, therefore, temsirolimus should be administered with caution in patients with a known hypersensitivity to sirolimus.

Because it is recommended that an H₁ antihistamine be administered to patients before the start of the intravenous temsirolimus infusion, TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons.

If a patient develops a hypersensitivity reaction during the TORISEL infusion despite the premedication, the infusion should be stopped and the patient should be observed for at least 30 to 60 minutes (depending on the severity of the reaction). At the discretion of the physician, treatment may be resumed with the administration of an H₁-receptor antagonist (such as diphenhydramine), if not previously administered (see DOSAGE AND ADMINISTRATION), and/or an H₂-receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. The infusion may then be resumed at a slower rate (up to 60 minutes). Diluted TORISEL should be administered within 6 hours of mixing (see DOSAGE AND ADMINISTRATION)

Skin

Rash NOS (all grades) was reported in 11 (5.5%) and 77 (37.0%) in the IFN and temsirolimus arms, respectively. Acne was common in the temsirolimus group with 21 (10.1%) reports, compared with 2 (1.0%) in the IFN arm.

Special Populations

Pregnant Women:

There are no adequate and well-controlled studies in pregnant women using TORISEL. In animal toxicity studies with rats and rabbits, there was increased embryo/fetal mortality and decreased fetal growth (see TOXICOLOGY).

Women of childbearing age should use medically acceptable contraception during (and up to 3 months after) treatment.

Temsirolimus should not be used during pregnancy (see TOXICOLOGY).

In addition, men should be adequately counseled prior to starting treatment with TORISEL and need to understand the possible danger of taking a medicinal product whose effects on the fetus and sperm are unknown. Men with partners of childbearing potential should use medically

acceptable contraception throughout treatment and are recommended to continue this for 12 weeks after the last dose of TORISEL.

Nursing Women:

It is not known whether TORISEL is excreted into human milk. Because many drugs are excreted into human milk, and because the effects of temsirolimus excretion in human milk have not been studied, women should be advised against breast-feeding while receiving temsirolimus.

Pediatrics:

Limited data are available on the use of TORISEL in pediatric patients. TORISEL has been studied in a total of 71 pediatric patients (59 patients ages 1 to 17 years, 12 patients ages 18 to 21 years) with advanced relapsed/refractory solid tumors in a phase I/II safety and exploratory pharmacodynamic study. The effectiveness of TORISEL in this pediatric population was not established.

Geriatrics (≥ 65 years of age):

No specific overall differences in safety were observed between patients younger than 65 or older than 65.

Based on the results of a phase 3 study for renal cell carcinoma, elderly patients may be more likely to experience certain adverse reactions, including edema, diarrhea, and pneumonia.

Overall survival in a subset of patients 65 years of age or older (N=64) treated with TORISEL was shorter than that observed with patients under 65 years of age (see CLINICAL TRIALS). The clinical relevance of this subgroup analysis is unclear.

No specific dose adjustment is recommended for elderly patients.

Renal Dysfunction:

Effect of renal impairment on TORISEL pharmacokinetics has not been studied (see WARNINGS AND PRECAUTIONS - Renal Dysfunction)

Hepatic Dysfunction:

TORISEL is contraindicated in patients with bilirubin >1.5 x ULN (see CONTRAINDICATIONS, WARNING AND PRECAUTIONS - Hepatic Dysfunction, DOSAGE AND ADMINISTRATION).

Monitoring and Laboratory Tests

In the randomized phase 3 trial, complete blood counts were checked weekly, and chemistry panels were checked every two weeks. In addition, it is recommended to measure fasting glucose and lipids prior to starting treatment, with regular follow up tests during the treatment period. Laboratory monitoring for patients receiving TORISEL must be individualized at the discretion of the treating physician.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The following serious adverse reactions have been associated with TORISEL (temsirrolimus concentrate for injection) in clinical trials and are discussed in greater detail in other sections of the label (see WARNINGS AND PRECAUTIONS):

- Hypersensitivity Reactions
- Hyperglycemia / Glucose Intolerance
- Infections
- Interstitial Lung Disease
- Renal Failure

The most common ($\geq 30\%$) adverse reactions observed with TORISEL are rash, asthenia, mucositis, nausea, edema, and anorexia. The most common ($\geq 30\%$) laboratory abnormalities observed with TORISEL are anemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia, thrombocytopenia, elevated AST, and leukopenia.

Clinical Trial Adverse Drug Reactions

Renal Cell Carcinoma Study 1 (3066K1-304-WW)

Study 1 is a phase 3, three-arm, randomized, open-label study of Interferon alfa (IFN- α) alone, TORISEL alone, and TORISEL and IFN- α . A total of 616 patients were treated. Two hundred patients received IFN- α weekly, 208 received TORISEL 25 mg weekly, and 208 patients received a combination of IFN- α and TORISEL weekly (see CLINICAL TRIALS).

Treatment with the combination of TORISEL 15 mg and IFN- α resulted in a statistically significant increase in the incidence of certain grade 3-4 adverse events (weight loss, hyperlipemia, anemia, neutropenia, thrombocytopenia and mucosal inflammation) when compared with the adverse events observed in the IFN- α or TORISEL 25 mg-alone arms. The combination did not result in a significant increase in overall survival when compared with IFN- α alone (8.4 vs 7.3 months, hazard ratio = 0.96, $p = 0.6965$).

Of the 208 patients treated in the temsirolimus alone arm, 88 (42.3%) patients had adverse events of nausea or vomiting or both. Of these 88 patients, 59 (67.0%) received at least one anti-emetic during their study participation. Temsirolimus was dose-reduced and discontinued in one patient due to vomiting. Of the 8 patients who reported grade 3 or 4 nausea or vomiting or both, 2 patients had a past medical history of nausea or vomiting at the time of screening, and 2 patients did not receive any anti-emetics to control their nausea or vomiting while on study.

Table 1 shows the percentage of patients experiencing treatment emergent adverse reactions reported in Study 1. Reactions reported in at least 10% of patients who received TORISEL 25 mg alone are listed. Data for the same adverse reactions in the IFN- α alone arm are shown for comparison.

Table 1: Adverse Reactions Reported in at Least 10% of Patients Who Received 25 mg IV TORISEL in Study 1.

Adverse Reaction	TORISEL 25 mg n=208		IFN- α n=200	
	All Grades ^a n (%)	Grades 3&4 ^a n (%)	All Grades ^a n (%)	Grades 3&4 ^a n (%)
Any	208 (100)	139 (67)	199 (100)	155 (78)
Blood and lymphatic system disorders				
Anemia	94 (45)	41 (20)	83 (42)	43 (22)
Thrombocytopenia	28 (14)	3 (1)	16 (8)	0 (0)
Gastrointestinal disorders				
Nausea	77 (37)	5 (2)	82 (41)	9 (4)
Diarrhea	56 (27)	3 (1)	40 (20)	4 (2)
Abdominal Pain	44 (21)	9 (4)	34 (17)	3 (2)
Stomatitis ^b	86 (41)	6 (3)	19 (10)	0 (0)
Vomiting	40 (19)	4 (2)	57 (29)	5 (3)
Constipation	43 (21)	0 (0)	37 (19)	1 (<1)
General disorders and administrative site conditions				
Asthenia	106 (51)	23 (11)	127 (64)	52 (26)
Edema ^c	88 (42)	7 (3)	25 (13)	1 (1)
Pain	59 (28)	10 (5)	31 (16)	4 (2)
Pyrexia	50 (24)	1 (1)	99 (50)	7 (4)
Chest Pain	34 (16)	2 (1)	18 (9)	2 (1)
Headache	32 (15)	1 (<1)	29 (15)	0 (0)
Infections and infestations				
Infections ^d	52 (25)	6 (3)	19 (10)	4 (2)
Urinary tract infection ^e	39 (19)	3 (1)	30 (15)	4 (2)
Pharyngitis	25 (12)	0 (0)	3 (2)	0 (0)
Rhinitis	25 (10)	0 (0)	4 (2)	0 (0)
Investigations				
Blood creatinine increased	30 (14)	6 (3)	21 (10)	1 (1)
Metabolism and nutrition disorders				
Anorexia	66 (32)	5 (2)	87 (44)	8 (4)
Hyperlipidemia	57 (27)	6 (3)	28 (14)	2 (1)
Hyperglycemia	53 (26)	22 (11)	22 (11)	3 (2)
Hypercholesteremia	51 (25)	1 (1)	9 (4)	0 (0)
Weight Loss	39 (19)	3 (1)	50 (25)	4 (2)
Musculoskeletal and connective tissue disorders				
Back Pain	41 (20)	6 (3)	28 (14)	3 (2)
Arthralgia	37 (18)	2 (1)	29 (15)	2 (1)
Nervous system disorders				
Dysgeusia ^f	41 (20)	0 (0)	17 (9)	0 (0)
Insomnia	24 (12)	1 (1)	30 (15)	0 (0)

Table 1: Adverse Reactions Reported in at Least 10% of Patients Who Received 25 mg IV TORISEL in Study 1. (Cont'd)

Adverse Reaction	TORISEL 25 mg n=208		IFN- α n=200	
	All Grades ^a n (%)	Grades 3&4 ^a n (%)	All Grades ^a n (%)	Grades 3&4 ^a n (%)
Respiratory, thoracic and mediastinal disorders				
Dyspnea	58 (30)	18 (9)	48 (24)	11 (6)
Cough	53 (26)	2 (1)	29 (15)	0 (0)
Epistaxis	25 (12)	0 (0)	7 (4)	0 (0)
Skin and subcutaneous tissue disorders				
Rash ^g	97 (47)	11 (5)	12 (6)	0 (0)
Pruritus	40 (19)	1 (1)	16 (8)	0 (0)
Nail Disorder	28 (14)	0 (0)	1 (1)	0 (0)
Dry Skin	22 (11)	1 (1)	14 (7)	0 (0)
Acne	21 (10)	0 (0)	2 (1)	0 (0)

a. Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0.

b. Includes aphthous stomatitis, glossitis, mouth ulceration, mucositis, and stomatitis

c. Includes facial edema and peripheral edema

d. Includes general infections and a variety of infections that occurred infrequently as distinct entities: cellulitis, herpes zoster, herpes simplex, bronchitis, and abscess

e. Includes dysuria, hematuria, urinary frequency, and cystitis

f. Includes taste loss and taste perversion

g. Includes pruritic rash, maculopapular rash, and pustular rash

The following adverse reactions were commonly reported ($\geq 1\%$ and $\leq 10\%$) and may be associated with the use of TORISEL:

Bleeding - GI haemorrhages (4%), haematuria (3.8%), urinary bladder haemorrhages (1.0%), hemoptysis (2.4%) (see WARNINGS AND PRECAUTIONS)

Eye Disorders - Conjunctivitis (including lacrimation disorder) (7%).

Gastrointestinal Disorders - Abdominal distension-(4%), gingivitis (2%), mouth pain (2%), fatal bowel perforation (1%), dysphagia (3%), gastritis (1%).

General Disorders and Administrative Site Conditions – Impaired wound healing (1%).

Immune System –Allergic/Hypersensitivity reactions (9%).

Infections and Infestations – Pneumonia (7%), upper respiratory tract infection (7%), flu syndrome (3%), oral moniliasis (2%), sinusitis (2%), folliculitis (2%), laryngitis (1.0%), wound infection/post-operative wound infection (1.0%), fungal infection/fungal dermatitis (2.0%).

Investigations - Aspartate aminotransferase increase (8%); Alanine aminotransferase increase (6%).

Metabolism and Nutritional Disorders - Diabetes mellitus (5%), dehydration (5%).

Psychiatric Disorders - Anxiety (8%), somnolence (7%), depression (4%)

Renal and Urinary Disorders – Acute Renal Failure, including fatalities (1.4%), dysuria (4.8%), renal pain (2.4%), proteinuria (2.0%), pollakiuria (1.4%), azotaemia (1.4%), urinary retention (1%).

Respiratory, Thoracic and Mediastinal Disorders - Pleural effusion (5%), interstitial lung disease/pneumonitis (2%), including fatal episodes, has been reported in patients taking temsirolimus.

Skin and Subcutaneous Tissue Disorders - Exfoliative dermatitis (8%).

Vascular - Hypertension (7%) (see WARNINGS AND PRECAUTIONS), venous thromboembolism (including deep vein thrombosis and pulmonary embolus [including fatal outcomes]) (2%), thrombophlebitis (1%).

The following adverse reactions were uncommonly reported ($\geq 0.1\%$ and $< 1\%$) and may be associated with the use of TORISEL:

Cardiac Disorders - Pericardial effusion (including hemodynamically significant pericardial effusions requiring intervention) (1%).

Nervous System Disorders – Dizziness (9%), paresthesia (6%), convulsion (0.5%).

Renal Cell Carcinoma Study 2 (3066K1-200-WW)

Study 2 was a phase 2, randomized, double-blind, multi-center, outpatient trial to evaluate the efficacy, safety, and pharmacokinetics of three dose levels of TORISEL when administered to previously treated patients with advanced RCC. One hundred eleven (111) patients were randomly assigned in a 1:1:1 ratio to receive 25 mg, 75 mg, or 250 mg TORISEL IV weekly. The incidence and type of adverse events reported for the temsirolimus 25 mg arm were generally similar to those reported in the pivotal phase 3 study (Study 1).

Abnormal Hematologic and Clinical Chemistry Findings

Table 2: Incidence of Clinically Important Laboratory Abnormalities Reported in at Least 10% of Patients who Received 25 mg IV TORISEL in Study 1

Laboratory Abnormality	TORISEL 25 mg n=208		IFN- α n=200	
	All Grades ^a n (%)	Grades 3&4 ^a n (%)	All Grades ^a n (%)	Grades 3&4 ^a n (%)
Any	208 (100)	139 (67)	199 (100)	155 (78)
Hematology				
Hemoglobin Decreased	195 (94)	41 (20)	180 (90)	43 (22)
Lymphocytes Decreased ^b	110 (53)	33 (16)	106 (53)	48 (24)
Neutrophils Decreased ^b	39 (19)	10 (5)	58 (29)	19 (10)
Platelets Decreased	84 (40)	3 (1)	51 (26)	0 (0)
Leukocytes Decreased	67 (32)	1 (1)	93 (47)	11 (6)
Chemistry				
Alkaline Phosphatase Increased	141 (68)	7 (3)	111 (56)	13 (7)
AST Increased	79 (38)	5 (2)	103 (52)	14 (7)
Creatinine Increased	119 (57)	7 (3)	97 (49)	2 (1)
Glucose Increased	186 (89)	33 (16)	128 (64)	6 (3)
Phosphorus Decreased	102 (49)	38 (18)	61 (31)	17 (9)
Total Bilirubin Increased	16 (8)	2 (1)	25 (13)	4 (2)
Total Cholesterol Increased	181 (87)	5 (2)	95 (48)	2 (1)
Triglycerides Increased	173 (83)	92 (44)	144 (72)	69 (35)
Potassium Decreased	43 (21)	11 (5)	15 (8)	0 (0)
Potassium Increased	46 (22)	10 (5)	68 (34)	9 (5)
Calcium Increased	46 (22)	8 (4)	46 (23)	12 (6)
Calcium Decreased	82 (39)	9 (4)	83 (42)	9 (5)
Albumin Decreased	108 (52)	3 (1)	121 (61)	12 (6)

a. NCI CTC version 3.0

b. Grade 1 toxicity may be under-reported for lymphocytes and neutrophils

Post-Marketing Adverse Drug Reactions

The following adverse reactions have been identified during the post-approval use of temsirolimus. Frequency determination of adverse events reported from the post marketing environment is not possible since the size of the population receiving the drug is largely undetermined.

Cardiovascular disorders:

Adverse reactions observed in the post marketing environment include delayed angioneurotic edema-type reactions (occurring two months following initiation of therapy) observed in some patients who received concomitant therapy with temsirolimus and angiotensin-converting enzyme (ACE) inhibitors (see WARNINGS AND PRECAUTIONS), pleural effusion, pericardial effusion (including hemodynamically significant pericardial effusions requiring intervention), cardiac arrest, and convulsion.

Hypersensitivity/Infusion Reactions:

Hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions), have been associated with the administration of temsirolimus (see WARNINGS AND PRECAUTIONS).

Musculoskeletal and connective tissue disorders:

There have been reports of rhabdomyolysis in patients who received TORISEL.

Respiratory disorders:

Cases of pulmonary embolus (including fatal outcomes) have been reported. Cases of Pneumocystis jiroveci pneumonia, some with fatal outcomes have also been reported (see WARNINGS AND PRECAUTIONS).

Skin and subcutaneous tissue disorders:

There have been reports of Stevens-Johnson Syndrome and hand-foot syndrome in patients who received TORISEL.

DRUG INTERACTIONS**Overview**

TORISEL in combination with sunitinib, gemcitabine or 5-fluorouracil has been associated with serious adverse drug reactions. Fatal cases of bowel perforation have been observed when TORISEL was combined with 5-fluorouracil.

CYP3A4 is the major CYP isozyme responsible for the metabolism of temsirolimus and sirolimus. Potential interactions may occur with drugs/foods/herbs that are inhibitors or inducers of this enzyme system.

Drug-Drug Interactions**Agents Inducing CYP3A Metabolism**

Co-administration of TORISEL with rifampicin (600 mg), a potent CYP3A4/5 inducer, had no significant effect on temsirolimus C_{max} (maximum concentration) and AUC, after intravenous administration, but decreased sirolimus C_{max} by 65% and AUC by 56%, and AUCsum (composite of temsirolimus AUC plus sirolimus AUC) by 41% compared to temsirolimus

treatment alone. Therefore, concomitant treatment with agents that have CYP3A4/5 induction potential should be avoided. The safety profile of temsirolimus at doses greater than 25 mg in the presence of a CYP3A4/5 inducer has not been evaluated in the context of compensation for the reduced sirolimus exposure (see OVERDOSAGE).

Agents Inhibiting CYP3A Metabolism

Co-administration of TORISEL (5 mg, 1/5th of the clinically recommended dose) with ketoconazole (400 mg), a potent CYP3A4 inhibitor to healthy subjects, had no significant effect on temsirolimus C_{max} or AUC; however, AUC of sirolimus increased 3.1-fold, and AUC_{sum} increased 2.3-fold compared to temsirolimus alone. A 51% increase in sirolimus half-life and 69% decrease in clearance were also observed.

Concomitant treatment of TORISEL with agents that have strong CYP3A4 inhibition potential should be avoided (see WARNINGS AND PRECAUTIONS).

Interactions with Drugs Metabolized by CYP3A4/5

Temsirolimus may inhibit the metabolic clearance of substrates of CYP3A4/5 including statins. Caution should be exercised if a statin is required for hyperlipidemia, since the risk of developing rhabdomyolysis may be increased. Patients on treatment with TORISEL who are co-prescribed a statin should be advised to report symptoms including muscle pain or weakness.

Interactions with Drugs Metabolized by CYP2D6

In a study with 23 healthy subjects, the concentration of desipramine (50 mg), a CYP2D6 substrate, was unaffected when 25 mg of TORISEL was co-administered. However, there was over 8 hour gap between the peak concentration of the two drugs when they were administered concurrently. The magnitude of the interaction may have been reduced. Caution should be taken when temsirolimus is co-administered with agents that are metabolized by CYP2D6.

Interactions with drugs that are P-glycoprotein substrates

In an in vitro study, temsirolimus inhibited the transport of digoxin, a P-gp substrate, with an IC₅₀ value of 2 µM. Clinical implications related to concomitant administration of P-gp substrates are not known.

Anti-emetic Agents

The safety of concomitant use of temsirolimus with anti-emetic agents, including but not limited to: prochlorperazine, diphenhydramine, metoclopramide, ondansetron, or domperidone, has not been formally studied.

Interactions with QT/QTc-prolonging drugs

The concomitant use of TORISEL with another QT/QTc-prolonging drug should be avoided to the extent possible.

Other Pharmacodynamic Interactions

An increased risk of angioedema is possible in patients taking mTOR (mammalian target of rapamycin) inhibitors in combination with ramipril and/or amlodipine. Caution should be used when temsirolimus is given concomitantly with an ACE inhibitor (e.g., enalapril, lisinopril, ramipril) (see WARNINGS AND PRECAUTIONS) or a calcium channel blocker (e.g., amlodipine).

Drug-Food Interactions

The effect of food on exposure following an intravenous dose of temsirolimus was not examined.

Drug-Herb Interactions

Interactions with herbal products have not been established. St John's Wort is a strong inducer of CYP3A4 and may decrease blood concentrations of temsirolimus metabolites (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing Considerations

- No special dosage modification is required for any of the populations that have been studied (e.g. gender, elderly).
- Limited data are available on the use of TORISEL in pediatric patients. The effectiveness of TORISEL in pediatric patients with advanced relapsed/refractory solid tumors was not established (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatric). Therefore, a dosing recommendation cannot be made.
- Studies in patients with varying renal impairment or in patients undergoing hemodialysis have not been conducted (see ACTION AND CLINICAL PHARMACOLOGY).
- Temsirolimus should be used with caution in patients with hepatic impairment (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS).

Recommended Dose and Dosage Adjustment

The recommended dose of TORISEL for advanced renal cell carcinoma is 25 mg, infused over a 30-60 minute period once a week.

Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. No special dosage modification is required for any of the populations that have been studied (e.g. gender, elderly).

In Study 1, 19.2% of patients receiving temsirolimus alone reported vomiting as an adverse event. The emetogenic potential of temsirolimus is low.

Dose Modification

Management of suspected drug reactions may require temporary interruption and/or dose reduction of TORISEL therapy. If a suspected reaction is not manageable with dose delays, then TORISEL may be reduced by 5 mg/week decrements.

Hepatic Impairment: TORISEL is contraindicated in patients with bilirubin $>1.5 \times$ ULN due to increased risk of death, including deaths due to progression of underlying cancer. For patients with mild hepatic impairment (bilirubin $>1-1.5 \times$ ULN or AST $>$ ULN but bilirubin \leq ULN), a reduction of the temsirolimus dose to 15 mg/week could be considered. Assessment of AST and bilirubin levels is recommended before initiation of temsirolimus and periodically thereafter, because dosage adjustment may be required in some patients based upon hepatic function (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, ACTION AND CLINICAL PHARMACOLOGY).

Administration

Instructions for Intravenous Administration

TORISEL (temsirolimus concentrate for injection and diluent) must be stored under refrigeration at 2°- 8°C and protected from light. During handling and preparation of admixtures, TORISEL should be protected from excessive room light and sunlight. TORISEL (temsirolimus concentrate for injection and diluent) should be inspected visually for particulate matter and discoloration prior to administration. Bags/containers that come in contact with TORISEL must be made of glass, polyolefin, or polyethylene. (Text revised for clarification)

DO NOT USE IF PARTICULATES ARE PRESENT. USE A NEW VIAL.

Premedication

Patients should receive prophylactic medication of intravenous diphenhydramine 25 to 50 mg (or equivalent) approximately 30 minutes before the start of each dose of TORISEL. If a hypersensitivity/infusion reaction develops during the temsirolimus infusion, the infusion should be stopped. Upon adequate resolution, and at the discretion of the physician, treatment may be resumed with the administration of an H₁-receptor antagonist (or equivalent), if not previously administered, and/or an H₂-receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the temsirolimus infusion. The infusion may then be resumed at a slower rate (up to 60 minutes)(see WARNINGS AND PRECAUTIONS).

Dilution

The diluted solution (concentrate and diluent) should be inspected visually for particulate matter and discoloration.

In preparing the TORISEL administration solution, follow this two-step dilution process in an aseptic manner.

Step 1:

Inject 1.8 mL of diluent for TORISEL concentrate into the vial containing TORISEL for injection. The vial containing TORISEL contains 30 mg of drug in 1.2 mL vehicle. The drug concentration after mixing will be 10 mg/mL. Allow sufficient time for air bubbles to subside. The solution is clear to slightly turbid, colorless to light yellow, essentially free from visual particulates. A 1.2 mL volume of drug concentrate contains a total of 30 mg of drug product. When 1.2 mL of drug concentrate is combined with 1.8 mL of diluent, a total volume of 3.0 mL is obtained. Thirty milligrams (30 mg) of drug product per 3.0 mL = 10 mg of drug product/mL. The drug concentrate-diluent mixture is stable for up to 24 hours at room temperature 20° to 25°C and protected from light. Any unused diluted mixture should be discarded after 24 hours.

Vial Size	Volume of Diluent to be Added to Vial	Approximate Available Volume	Nominal Concentration per mL
25 mg/mL (1.2 mL of drug concentrate)	1.8 mL of diluent	3.0 mL	10 mg/mL

Step 2:

Withdraw the required amount (2.5 mL) of TORISEL concentrate/diluent mixture from step 1 (10 mg/mL) and inject rapidly into 250 mL of 0.9% sodium chloride injection to ensure adequate mixing. Mix the admixture by inversion of the bag or bottle. Avoid excessive shaking as this may cause foaming.

The final diluted solution in the bag or bottle should be inspected visually for particulate matter.

Administration

- Administration of the final diluted infusion solution should be completed within six hours from the time that the concentrate-diluent mixture is added to the sodium chloride injection.
- TORISEL is administered as an IV solution over a 30-60 minute period once a week. The use of an infusion pump is the preferred method of administration to ensure accurate delivery of the drug.
- Appropriate administration materials must be composed of glass, polyolefin, or polyethylene to avoid excessive loss of drug and to decrease the rate of di-(2-ethylhexyl) phthalate (DEHP) extraction. The administration materials must consist of non-DEHP non-polyvinyl chloride (PVC) tubing with the recommended in-line filter. An in-line polyethersulfone filter with a pore size of not greater than 5 microns is recommended for administration to avoid the possibility of particles bigger than 5 microns being infused. If the administration set available does not have an in-line filter incorporated, a filter should be added at the end of the set (i.e., an end-filter) before the admixture reaches the vein of

the patient. Different end-filters can be used ranging in filter pore size from 0.2 microns up to 5 microns. The use of both an in-line and end-filter is not recommended. It is important that the recommendations in DOSAGE AND ADMINISTRATION be followed closely.

- TORISEL concentrate, when constituted, contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from PVC. This should be considered during the preparation and administration of TORISEL, including storage time elapsed in a PVC container following constitution. It is important that the recommendations in DOSAGE AND ADMINISTRATION be followed closely.

Compatibilities, Incompatibilities

TORISEL concentrate for injection should not be added directly to aqueous infusion solutions. Direct addition of TORISEL concentrate for injection to aqueous solutions will result in precipitation of drug. Always combine TORISEL concentrate for injection with diluent for TORISEL concentrate for injection before adding to infusion solutions. It is recommended that temsirolimus be administered in 0.9% sodium chloride injection after combining with diluent. The stability of temsirolimus in other infusion solutions has not been evaluated. Addition of other drugs or nutritional agents to admixtures of temsirolimus in sodium chloride injection has not been evaluated and should be avoided. Temsirolimus is degraded by both acids and bases, and thus combinations of temsirolimus with agents capable of modifying solution pH should be avoided.

OVERDOSAGE

There is no specific treatment for TORISEL intravenous overdose. TORISEL has been administered to patients with cancer with repeated intravenous doses as high as 220 mg/m² (396 mg). However, the risk of serious adverse events including thrombosis, CNS hemorrhage, melena, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of TORISEL greater than 25 mg.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin)². mTOR inhibition is implicated in preventing the proliferation of a number of tumour cell types and angiogenesis. Temsirolimus binds to an intracellular protein (FKBP12), and the protein-drug complex binds and inhibits the activity of mTOR that controls cell division. Inhibition of mTOR

activity results in a G1 growth arrest in treated tumor cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase. Temsirolimus exerts its effect by binding in a complex with FKBP-12 and mTOR. When mTOR is bound in this complex, its ability to phosphorylate, and thereby control the activity of protein translation factors (4E-BP1 and S6K, both downstream of mTOR in the P13 kinase/AKT pathway) that control cell division, is blocked. In addition to regulating cell cycle proteins, mTOR can regulate translation of the hypoxia-inducible factors, HIF-1 and HIF-2 alpha. These transcription factors regulate the ability of tumors to adapt to hypoxic microenvironments and to produce the angiogenic factor vascular endothelial growth factor (VEGF)³. The anti-tumor effect of temsirolimus, therefore, may also in part stem from its ability to depress levels of HIF and VEGF in the tumor or tumor microenvironment, thereby impairing vessel development.

Pharmacodynamics

The effect of TORISEL on the inhibition of phosphorylation of S6-ribosomal protein in circulating lymphocytes was examined in 30 healthy male subjects. Data indicate that inhibition of protein phosphorylation was rapid and dose-dependent. Following a single 25 mg dose of TORISEL, 50% of maximal inhibition of S6-ribosomal protein in CD3+ cells was shown for at least 3 days.

Cardiac Electrophysiology: The cardiac electrophysiology of a single 25 mg intravenous dose of temsirolimus was studied in 58 healthy male volunteers (18-50 years) in a fixed sequence, three period crossover design trial. In periods 1 and 2, the subjects were randomized to receive single-blind placebo IV infusion either alone or with open label oral moxifloxacin 400 mg. In period 3, all subjects were administered single-blind temsirolimus 25 mg IV.

Temsirolimus resulted in a statistically significant increase in the QTc interval from 1 to 48 hours post-dosing. The 48 hour ECG collection period in this study was not sufficiently long to characterize the offset of the effect. The maximum increase was 8.05 ms (90% CI 5.77, 10.34 ms) at 36 hours post-dosing.

In a different trial in patients with a hematologic malignancy, 103 patients receiving TORISEL doses up to 175 mg were studied for QTc effects. One subject with normal QTcF at baseline exhibited a QTcF increase > 60 ms by week 12 of treatment.

Many drugs that cause clinically significant QT/QTc prolongation are suspected to increase the risk of torsade de pointes. Temsirolimus should be administered with caution in patients who have or may develop prolongation of QTc interval. These include patients with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking anti-arrhythmic medicines or other medicinal products that lead to QTc prolongation, and cumulative high-dose anthracycline therapy.

Pharmacokinetics

Following a single 25 mg intravenous dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus (see Table 3). Following varying IV temsirolimus doses, the AUC_{sum} in whole blood increased in a dose-related, but non-proportional manner.

Table 3: Mean (SD) Pharmacokinetic Parameters^a of Temsirolimus and Sirolimus in Whole Blood of Patients Following a Single 25-mg Intravenous Dose of Temsirolimus

	C _{max} (ng/mL)	AUC (ng*h/mL)	AUC _{sum} ^b (ng Eq's*h/ML)	T _{max} (h)	T _{1/2} (h)
Temsirolimus	585.4 ± 83.1	1627 ± 425	.	1.0 ± 0	17.3 ± 5.9
Sirolimus	55.4 ± 31.8	4151 ± 1600	5778 ± 1722	2.0 ± 0	54.6 ± 1.5

a. N=13. For C_{max}, N=5; for T_{1/2}, N=2

b. AUC_{sum} expressed relative to temsirolimus equivalents

Distribution:

Temsirolimus exhibits a polyexponential decline in whole blood concentrations and distribution and is attributable to preferential binding to FKBP-12 in blood cells⁴. The mean (standard deviation, SD) dissociation constant (K_d) of binding was 5.1 (3.0) ng/mL, denoting the concentration at which 50% of binding sites in blood cells were occupied. Temsirolimus distribution is dose-dependent with mean (10th, 90th percentiles) maximal specific binding in blood cells of 1.4 mg (0.47 to 2.5 mg). Following a single 25 mg intravenous dose, mean steady-state volume of distribution in whole blood of patients with cancer was 172 liters. *In vitro* temsirolimus binding to plasma proteins was approximately 87% at the concentration of 100 ng/mL.

Metabolism:

Temsirolimus is metabolized primarily by CYP3A4 in human liver. It is also a substrate and potential inhibitor of P-glycoprotein. Sirolimus, an equally potent metabolite to temsirolimus was observed as the principal metabolite in humans following intravenous administration.

Additional metabolic pathways were hydroxylation, reduction and demethylation in *in vitro* temsirolimus metabolism studies.

Temsirolimus inhibited CYP3A4/5 and CYP2D6 in human liver microsome studies with C_{\max}/K_i ratio values of 0.19 and 0.38, respectively. Following a single 25 mg intravenous dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus.

Excretion:

Following administration of a single dose of [^{14}C]-labeled temsirolimus, excretion was predominantly via the feces (78%), with renal elimination of drug and metabolites accounting for 4.6% of the administered radioactivity. Approximate 17% of the total radioactivity was not recovered from either route following 14-day sample collection. Mean (CV) systemic clearance was 16.2 (22%) L/h. Mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.

Special Populations and Conditions

Pediatrics:

The effectiveness of TORISEL in the pediatric population was not established (see INDICATIONS AND CLINICAL USE and WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics.)

Geriatrics:

In population pharmacokinetic-based data analyses, age did not have a significant effect on the disposition of temsirolimus or sirolimus metabolite.

Gender:

In population pharmacokinetic-based data analyses, gender did not have a significant effect on the disposition of temsirolimus or sirolimus metabolite.

Race:

In a study of ten Japanese patients (mean [range] body surface area of 1.6 m² [1.4 to 1.8 m²]), seven patients received an intravenous administration of 15 mg/m² dose of temsirolimus (24 mg [21 to 28 mg]). In these patients, the whole blood mean (SD) C_{\max} was 1014 (316) ng/mL, AUC_{sum} was 11041 (1935) ng Eq's·h/mL, and clearance was 8.48 (1.73) L/h. The total exposure level and C_{\max} of temsirolimus in Japanese patients were significantly higher than those of non-Japanese patients following a 25 mg dose (see Table 3 for comparison).

Renal Cell Carcinoma:

In an integrated population pharmacokinetic-based data analysis, patients with RCC exhibited an increase in apparent clearance of sirolimus of 24.8% compared to healthy subjects and

patients without RCC. Temsirolimus exposure was not affected by presence or absence of RCC.

Hematocrit:

In a phase II study of RCC patients treated with temsirolimus, increased hematocrit was associated with increased trough drug concentrations in the blood [for hematocrit increase from 25% to 55%, end-of-week [temsirolimus+sirolimus] whole blood trough concentrations were 2.7 to 6.0 ng/mL; peak concentrations were unaffected (691 to 678 ng/mL)].

Hepatic Insufficiency:

Temsirolimus is cleared predominantly by the liver. Temsirolimus is contraindicated in patients with bilirubin >1.5 x ULN. Temsirolimus should be used with caution in patients with hepatic impairment (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).

Dose de-escalation and multiple dose interruption were observed in patients with mild hepatic impairment primarily due to thrombocytopenia. For patients with mild hepatic impairment (bilirubin >1-1.5 x ULN or AST >ULN but bilirubin ≤ULN), a reduction of the temsirolimus dose to 15 mg/week could be considered.

Table 4: Temsirolimus Mean (± SD) PK Parameters in Subjects With Normal and Mild Hepatic Impairment

Hepatic function	AUC (ng*h/mL) – Day 1 (N)	AUC _{ss} (ng*h/mL) – Day 8 (N)
Normal ^a	2230 ± 426 (6)	1900 ± 245 (6)
Mild ^b	3050 ± 1050 (17)	4090 ± 4430 (12)

N= number of patients

a = bilirubin and AST ≤ULN

b = bilirubin >1 – 1.5 x ULN or AST >ULN but bilirubin ≤ULN

For patients with mild hepatic impairment, a reduction of the temsirolimus dose to 15 mg could be considered to provide a degree of temsirolimus exposure in blood, which approximates those following the 25 mg dose in patients with normal liver function (see WARNINGS AND PRECAUTIONS).

Renal Insufficiency:

Studies in patients with varying renal impairment have not been conducted. Caution should be taken when TORISEL is administered to patients with renal impairment.

TORISEL concentrate for injection has not been studied in patients undergoing hemodialysis.

STORAGE AND STABILITY

TORISEL (temsirolimus concentrate for injection) must be stored refrigerated (2° - 8°C) and protected from light.

TORISEL (temsirolimus concentrate for injection) and Diluent for TORISEL are co-packaged in a single carton, and must be stored refrigerated (2° - 8°C). Protect from light.

TORISEL or Diluent for TORISEL should not be used after the expiry date stated on the label.

The drug concentrate-diluent mixture is stable for up to 24 hours at controlled room temperature 20° - 25°C and protected from light. Any unused diluted mixture should be discarded after 24 hours.

Admixtures containing temsirolimus with 0.9% sodium chloride for injection should be used within 6 hours of preparation and should be stored at room temperature and protected from excessive light and sunlight. Any unused admixture should be discarded after 6 hours.

SPECIAL HANDLING INSTRUCTIONS

TORISEL (temsirolimus concentrate for injection) should be protected from excessive room light and sunlight during handling and preparation of admixtures. TORISEL should be inspected visually for particulate matter and discoloration following reconstitution and prior to administration. Bags/containers that come in contact with TORISEL must be made of glass, polyolefin, or polyethylene.

Once the concentrate is combined with the provided diluent, inject the mixture rapidly into 0.9% sodium chloride for injection. Administration of the final diluted infusion solution should be completed within six hours from the time that the concentrate is first diluted with the diluent.

Intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration, and leakage prior to administration. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

DOSAGE FORMS, COMPOSITION AND PACKAGING

TORISEL (temsirolimus) concentrate for injection, 30 mg in 1.2 mL (25 mg/mL) per vial.

DILUENT for TORISEL (temsirolimus) concentrate for injection, 1.8 mL per vial.

These two vials are co-packaged in a single carton, and must be stored at 2°-8°C. Protect from light.

Composition

TORISEL (temsirolimus) concentrate for injection

Active ingredient: Temsirolimus

Inactive ingredients: dehydrated alcohol, *d,l*-alpha-tocopherol, propylene glycol, anhydrous citric acid.

DILUENT for TORISEL (temsirolimus) concentrate for injection

Inactive ingredients: polysorbate 80, polyethylene glycol 400 macrogol, dehydrated alcohol (anhydrous ethanol).

Packaging

TORISEL concentrate for injection and diluent are filled in clear glass vials with butyl rubber stoppers. A color-coded seal will be used with TORISEL concentrate for injection and with the diluent.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Common name: Temsirolimus

Chemical name: (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34*a*-Hexadecahydro-9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4*H*,6*H*,31*H*)-pentone 4'-[2,2-bis(hydroxymethyl)propionate]; or Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]

Molecular formula: C₅₆H₈₇NO₁₆

Molecular mass: 1030.30

Structural formula:



Physicochemical properties:

Physical Form: white to off-white powder

Solubility: insoluble in water and soluble in alcohol. It has no ionizable functional groups, and its solubility is independent of pH.

CLINICAL TRIALS

The safety and efficacy of TORISEL in the treatment of advanced renal cell carcinoma (RCC) were studied in the following two randomized clinical trials (Study 1 and Study 2) used to support the original market authorization.

Renal Cell Carcinoma Study 1 (3066K1-304-WW)

Study demographics and trial design

Study 1 was a phase 3, multi-center, three-arm, randomized, open-label study in previously untreated patients with advanced renal cell carcinoma and with 3 or more of 6 pre-selected prognostic risk factors (less than one year from time of initial RCC diagnosis to randomization, Karnofsky performance status of 60 or 70, hemoglobin less than the lower limit of normal, corrected calcium of greater than 10 mg/dL, lactate dehydrogenase > 1.5 times the upper limit of normal, more than one metastatic organ site). The primary study endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate, time to treatment failure (TTF), and quality adjusted survival measurement. Patients were stratified for prior nephrectomy status within three geographic regions and were randomly assigned (1:1:1) to receive Interferon alfa (IFN- α) alone (N=207), TORISEL alone (25 mg weekly; N=209), or the combination of TORISEL and IFN- α (N=210).

The combination of TORISEL 15 mg and IFN- α did not result in a significant increase in overall survival when compared with IFN- α alone (median 8.4 vs 7.3 months, hazard ratio = 0.96, p = 0.6965) (see ADVERSE REACTIONS). Information on the TORISEL 25 mg-alone and IFN- α alone arms is described in this section.

The demographic and disease characteristics of the study population are shown in Table 5. Baseline demographic and disease characteristics were well balanced across treatment arms.

Table 5: Demographic and Other Baseline Characteristics For Patients in Clinical Study 1

Characteristic	TORISEL 25 mg n (%)	IFN- α n (%)
Total patients in treatment arm	209	207
Age		
< 65 years	145 (69.4)	142 (68.6)
\geq 65 years	64 (30.6)	65 (31.4)
Sex		
Female	70 (33.5)	59 (28.5)
Male	139 (66.5)	148 (71.5)
Race		
White	186 (89.0)	191 (92.3)
Asian	6 (2.9)	4 (1.9)
Black	9 (4.3)	8 (3.9)
Other	8 (3.8)	4 (1.9)
Prior nephrectomy		
No	70 (33.5)	68 (32.9)
Yes	139 (66.5)	139 (67.1)
Stage of disease at baseline		
Stage IV	200 (95.7)	201 (97.1)
Recurrent Stage II	1 (0.5)	1 (0.5)
Recurrent Stage III	8 (3.8)	5 (2.4)
Primary cell type		
Clear	169 (80.9)	170 (82.1)
Indeterminate	24 (11.5)	23 (11.1)
Non-clear	13 (6.2)	13 (6.3)
Unknown	3 (1.4)	1 (0.5)

Study results

In Study 1, TORISEL 25 mg was associated with a statistically significant advantage over IFN- α in the primary endpoint of OS (time from randomization to death). The advantage in OS was seen both in clear cell and non-clear cell subtypes. The TORISEL arm showed a 49% increase in median OS compared with the IFN- α arm. Figure 1 is a Kaplan-Meier plot of OS in Study 1.

TORISEL also was associated with statistically significant advantages over IFN- α in the secondary endpoints of PFS (time from randomization to disease progression or death, censored at the last tumor evaluation date), TTF (time from randomization to disease progression, death, withdrawal from treatment due to adverse event, withdrawal of voluntary consent, or loss to follow up), and clinical benefit rate (complete response, partial response, or stable disease for \geq 24 weeks). The evaluations of PFS, ORR, and clinical benefit rate were based on the investigator's assessment of disease progression. Efficacy results are summarized in Table 6.

Figure 1: Kaplan-Meier Curves for Overall Survival – Study 1




Table 6: Summary of Efficacy Results in TORISEL Clinical Study 1^a

Parameter	TORISEL n = 209	IFN- α n = 207	P-value ^b	Hazard Ratio (95% CI) ^c
Median Overall Survival Months (95% CI)	10.9 (8.6, 12.7)	7.3 (6.1, 8.8)	0.0078 ^d	0.73 (0.58, 0.92)
Median Progression-Free Survival Months (95% CI)	3.8 (3.6, 5.2)	1.9 (1.9, 2.2)	0.0005	0.69 (0.57, 0.85)
Overall Response Rate % (95% CI)	8.6 (4.8, 12.4)	7.7 (4.1, 11.4)	0.7460 ^e	NA
Median Time to Treatment Failure Months (95% CI)	3.8 (3.5, 3.9)	1.9 (1.7, 1.9)	<0.0001	0.61 (0.50, 0.74)
Clinical Benefit Rate % (95% CI)	33.0 (26.6, 39.4)	17.9 (12.7, 23.1)	0.0004 ^e	NA

a. Based on investigator assessment

b. Based on log-rank test stratified by prior nephrectomy and region.

c. Based on Cox proportional hazard model stratified by prior nephrectomy and region.

d. A comparison is considered statistically significant if the p-value is <0.0159 (O'Brien-Fleming boundary at 446 deaths).

e. Based on Cochran-Mantel-Haenszel test stratified by prior nephrectomy and region.

CI = confidence interval; NA = not applicable

In clinical Study 1, 31% of patients treated with TORISEL were 65 or older. Median overall survival for patients treated with TORISEL was 12 months (95% CI 9.9-14.5) with hazard ratio of 0.62 (95% CI 0.47-0.82), compared with IFN- α in patients younger than 65, and was 8.6 months (95% CI 6.4-11.5) with hazard ratio of 1.08 (95% CI 0.71-1.63) in patients 65 or older.

Quality Adjusted Survival

Quality adjusted survival was compared across treatment groups using the Q-TWiST approach^{5,6}. Survival was value-weighted by the patient based on presence or absence of toxicity or progression by completing the EuroQoL 5D (EQ-5D) scale at baseline, weeks 12 and 32, when a grade 3 or 4 toxicity was reported, upon relapse or progression, or upon withdrawal from the study. TORISEL 25 mg is associated with a statistically significant increase in quality adjusted survival (Q-TWiST) time of an estimated 1.3 months (7.0 vs. 5.7 months, 23%, p = 0.00145) as compared to IFN- α .

Renal Cell Carcinoma Study 2 (3066K1-200-WW)

Study demographics and trial design

Study 2 was a phase 2, randomized, double-blind, multi-center, outpatient trial to evaluate the efficacy, safety, and pharmacokinetics of three dose levels of TORISEL when administered to previously treated patients with advanced RCC. The primary efficacy endpoint was objective response rate (ORR). Clinical benefit rate, PFS, and OS were also evaluated. PFS was defined as time from the first dose of TORISEL to disease progression or death. One hundred eleven (111) patients were randomly assigned in a 1:1:1 ratio to receive 25 mg, 75 mg, or 250 mg TORISEL IV weekly. In the 25 mg arm (n = 36), all patients had metastatic disease; 4 (11%) had no prior chemo- or immunotherapy; 17 (47%) had one prior treatment, and 15 (42%) had 2 or more prior treatments for RCC. Twenty-seven (27, 75%) had undergone a nephrectomy. Twenty-four (24, 67%) were Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1, and 12 (33%) were ECOG PS = 0.

Study results

Efficacy endpoints were based on investigator assessment. For patients treated weekly with 25 mg intravenous TORISEL, the ORR was 5.6% (95% CI: 0.7, 18.7%), median OS was 13.8 months (95% CI: 9.0, 18.7 months), median PFS was 6.3 months (95% CI: 3.6, 7.8 months), and clinical benefit rate was 52.8% (95% CI: 35.5, 69.6%).

For patients treated weekly with 75 mg and 250 mg there was not a significant increase in overall survival compared with patients treated with 25 mg.

DETAILED PHARMACOLOGY

Nonclinical Pharmacology

In vitro Pharmacology

Temsirolimus was tested *in vitro* for its ability to inhibit the growth of a panel of 23 human tumor cell lines. A similar set of *in vitro* experiments was performed with temsirolimus at the National Cancer Institute (NCI) U.S.A. on a larger panel (51 cell lines) of human tumors. Hematopoietic and solid tumor lines from patients bearing lung, colon, breast, prostate, renal, CNS, melanoma and ovarian cancers were studied. In each tumor type, there were examples of sensitive lines that responded to temsirolimus with an IC₅₀ for growth of 10 nM.

In vivo Pharmacology

Human tumor cell lines grafted on the flanks of immunodeficient nude mice were studied to determine the efficacy of temsirolimus *in vivo*. Mouse / human tumor xenografts from renal, breast, prostate, pancreatic, colon, glioblastoma, and melanoma were established. In each tumor type evidence of growth inhibition with temsirolimus treatment was observed.

Safety Pharmacology

In single-dose intravenous (IV) central nervous system (CNS) and respiratory safety pharmacology studies in male rats administered temsirolimus at dosages up to 5 mg/kg, there were no biologically significant effects on CNS or respiratory function.

In human embryonic kidney cells, temsirolimus produced a concentration-dependent inhibition of the hERG potassium ion current by 13.3% at 3 μ M and 28.0% at 10 μ M (nominal concentrations). Higher concentrations could not be tested because of limited solubility preventing definition of the IC₅₀. The concentrations tested exceed the mean unbound C_{max} of temsirolimus observed in cancer patients (0.0738 μ M).

The cardiovascular studies did not provide sufficient information to evaluate the cardiovascular safety of intravenous administration of temsirolimus.

Nonclinical Pharmacokinetics

The pharmacokinetic profile of temsirolimus in animal species (mouse, rat, and monkey) is represented by significant conversion of temsirolimus to sirolimus in mice, with a substantially smaller amount of conversion in rats and monkeys. In humans, sirolimus represents the predominant component in the blood.

Temsirolimus demonstrates moderate (85% to 87%) binding to plasma proteins at concentrations of 10 and 100 ng/mL with an apparent concentration-dependent binding to erythrocytes. Temsirolimus is converted to sirolimus via a presumed esterase-mediated hydrolysis of the C42 ester bond, and species differences in the sirolimus:temsirolimus exposure ratios (high in mice and humans and low in rats and monkeys) may be affected both by species differences in hydrolytic activity and differences in the concentration of FKBP-12 in erythrocytes.

There were species differences in the uptake of both temsirolimus and sirolimus into formed blood elements resulting in whole blood:plasma ratios that are highest in humans and monkeys and lower in rats and mice, and may be related to species differences in the concentration of FKBP-12 in erythrocytes. Temsirolimus is well distributed in the tissues, with tissue:blood ratios indicative of slower CL_T from tissues than from blood. The tissues with the highest tissue:blood radioactivity were similar after IV and oral dosing and were generally not associated with tissue specific target organ toxicity related to the higher exposure. The tissue:blood ratio for kidney was > 10 after both oral and IV administration. The lower fetal exposure observed on GD 16 compared with GD 9 may in part be related to the development of P-glycoprotein activity in the mature placenta and the ability of temsirolimus to act as a substrate for P-glycoprotein-mediated efflux, suggesting that the placenta may play a significant role in protecting the fetus from exposure to maternally administered temsirolimus. However, pregnant female rats were exposed to low levels of temsirolimus compared to clinical exposure. Therefore it is not known whether the mature placenta plays a significant role in protecting the fetus from exposure to temsirolimus at clinically relevant doses.

The primary metabolites of temsirolimus in rats and monkeys are hydroxy-temsirolimus (M10) and seco-temsirolimus (M4). Oral administration of temsirolimus resulted in a more extensive number of circulating metabolites with temsirolimus as the major circulating compound-related product in rat and monkey whole blood, followed by sirolimus as the next most abundant metabolite. In humans, temsirolimus was readily metabolized to sirolimus, and the major compound-related components in human whole blood were temsirolimus, sirolimus, and the oxidative metabolites of temsirolimus or sirolimus. Other expected metabolites, as determined from human liver microsomal studies, include various demethylated and hydroxylated isomeric forms of temsirolimus and sirolimus, and the seco (ring opened) form of both temsirolimus and sirolimus. There is evidence of more extensive metabolism in the feces of rats compared with blood and plasma, suggesting further biotransformation during elimination. The primary oxidative metabolism is via CYP3A4, indicating that inhibitors and inducers of CYP3A4 enzyme system may alter the metabolism of temsirolimus. Temsirolimus does not induce CYP3A4 at the transcription level. Temsirolimus may inhibit the metabolic clearance of substrates of CYP3A4/5 or CYP2D6, but not CYP2C9 or CYP2C8.

TOXICOLOGY

The metabolism of temsirolimus in rats and monkeys is different than in humans. Temsirolimus is readily converted into sirolimus in humans but not in rats and monkeys. The toxicity studies in rats and monkeys provided essential information on the toxicity of temsirolimus. However, they did not provide sufficient information on the toxicity of sirolimus at the exposure level observed in humans administered a clinical dose of temsirolimus.

Single-Dose Toxicity

The single-dose toxicity of temsirolimus was assessed in IV and oral studies in mice and rats and after the first dose in repeat-dose toxicity studies in monkeys. In a single-dose toxicity study, after IV administration of 50 mg/kg in mice, there was no mortality. However, in genotoxicity studies, after IV administration of a single-dose of temsirolimus in mice, mortality was reported at dosages of 4, 10, 25 and 100 mg/kg. Decreased motor activity and ptosis were observed in the male group. Based on the results of 2 IV studies in rats, the median lethal dosage was approximately 50 mg/kg. After oral (gavage) administration of 100 mg/kg, there was no mortality in either species. After the first dose in repeat-dose toxicity studies in monkeys, there was no mortality and temsirolimus was well tolerated at IV dosages up to 2.5 mg/kg and oral dosages up to 7.5 mg/kg (the highest dosages administered by each route).

Repeat-Dose Toxicity

Toxicity studies with temsirolimus were conducted by the IV and oral routes of administration in rats and monkeys and by the oral route in mice. Findings after IV and oral administration were similar. Many of these effects were attributable to the pharmacologic antiproliferative effects of temsirolimus or were considered to be secondary to the antiproliferative effects.

In the 3-month oral toxicity study in mice, there were 3 temsirolimus-related deaths; 1 female at 10 mg/kg and 1 male and 1 female at 100 mg/kg were euthanized due to poor and/or

deteriorating condition considered to be secondary to the antiproliferative effects of temsirolimus. In the repeat-dose toxicity studies in monkeys, 3 female monkeys were euthanized due to temsirolimus-related moribundity (ie, thin appearance and fecal alterations). These deaths occurred in 1 female at 0.1 mg/kg and 1 female at 2.5 mg/kg in the IV 9-month (once-weekly dosing) study and in 1 female at 0.5 mg/kg in the oral 3-month (once-daily dosing) study. Necropsy on the euthanized animals from the IV study showed microscopic erosions, cysts, or mixed cell inflammation in the cecal or colonic mucosa, and lymphoid atrophy in the thymus, mandibular lymph node, mesenteric lymph node, and /or gut associated lymphoid tissue (GALT).

Lymphoid atrophy of the thymus and lymphoid tissues was seen in mice, rats, and monkeys and was attributed to the antiproliferative activity of temsirolimus on lymphoid tissue. Lymphoid atrophy was associated with decreased peripheral blood lymphocytes in some studies in mice, rats, and monkeys. Bone marrow hypocellularity was observed in rats and may have been due to an antiproliferative effect on the lymphoid elements in the bone marrow. Lymphoid elements are present at higher levels in rat bone marrow than in bone marrow from other species, including nonhuman primates and humans, and may account for the rat-specific nature of this finding. Reversibility of hematology parameters was demonstrated during the interval between dosing cycles in the 4-cycle IV studies in rats and monkeys.

Hyperglycemia and pancreatic islet cell vacuolation were observed in rats. Additionally in rats, findings that were considered to be associated with hyperglycemia included cataracts, hepatocellular vacuolation, and renal tubular vacuolation.

Small testes, decreased testis weights, testicular tubular degeneration, testicular tubular giant cells, and/or hypospermia were observed in mice, rats, and monkeys. Based on severity, some instances of severe testicular tubular degeneration in rats administered IV dosages of 2.5 mg/kg may not have been reversible. Also observed in rats were decreased prostate weights; small seminal vesicles, epididymides, and prostates; and the presence of immature spermatocytes in the epididymides. The findings in the male reproductive system were considered to be secondary to the testicular tubular degeneration. Changes in the male reproductive system were consistent with the antiproliferative effects of temsirolimus, as well as a decrease in testosterone levels. Testosterone levels have not been determined in monkey studies with temsirolimus or sirolimus; however, decreases in testicular testosterone levels were noted in studies with sirolimus in rats and were partially attributed to sirolimus-induced suppression of testicular mitochondrial steroid side-chain cleavage activity.

Lameness, with or without evidence of bone fracture, was observed in rats (primarily males) administered temsirolimus. Although the specific cause of the lameness seen in rats administered temsirolimus is unknown, sirolimus is known to induce lameness associated with osteopenia and bone fracture in male rats that was associated with a decrease in testosterone.

Decreased ovary weights and microscopic atrophy of the ovaries, uterus, and cervix, and/or luteal or follicular cysts were observed in rats. The etiology of these findings is unknown, but

decreased body weight may have had an influence. In addition to the changes observed in the rat repeat-dose toxicity studies, functional effects (decreased corpora lutea) were observed in a rat female fertility dose-ranging study.

Inflammation of the cecum/colon and fecal alterations (diarrhea, soft or unformed stools, or mucoid and/or liquid feces) were observed in monkeys. These findings were considered secondary to the antiproliferative effects of temsirolimus, including atrophy of the gastrointestinal-associated lymphoid tissue (GALT), and to the alteration of normal flora in the bowel. Clinical pathology changes (increased fibrinogen and neutrophils) consistent with mild inflammatory changes in the cecum and colon were observed in monkeys.

Abrasions, inflammation, and/or ulceration of the skin were observed in rodents and were consistent with the antiproliferative effect of temsirolimus on regenerating tissue and the immune system. The skin lesions seen in mice were consistent with ulcerative dermatitis, a well-recognized condition in mice. Clinical pathology changes (increased fibrinogen and neutrophils and decreased albumin and increased globulin) consistent with mild inflammation were observed in mice and rats. Rashes were observed in monkeys in the IV 9-month study.

Myocardial degeneration was observed in rats and mice. Myocardial degeneration occurs spontaneously in untreated laboratory rats and progresses in incidence and severity with age, particularly in male rats. In rats given temsirolimus, this progression was seen earlier than in age-matched controls with increased incidence and severity. In mice, cardiomyopathy was reported in 1 out of 10 females dosed 100mg/kg for 2 weeks. One case of heart amyloidosis was reported in a mouse female that received temsirolimus at an oral dose of 100 mg/kg for 3 months. Increased incidence and severity of myocardial degeneration (sometimes described as spontaneous rat cardiomyopathy) was an exacerbation of a naturally occurring condition in rats and may not be relevant to humans.

Increased numbers of pulmonary alveolar macrophages were seen in rats without appreciable inflammatory change and were consistent with phospholipidosis. Accumulation of phospholipid in rat pulmonary alveolar macrophages is associated with a variety of different compounds and is generally not predictive of adverse findings in humans. Increased pulmonary alveolar macrophages with phospholipid accumulation have not occurred in mice or monkeys given temsirolimus. The appearance and etiology of the changes in the lung are distinct from interstitial pneumonitis (observed in clinical studies with temsirolimus) and there is no relationship between the 2 conditions.

Increased cholesterol was seen in mice, rats, and monkeys. Although the increases were generally of low magnitude and not considered adverse, hypercholesterolemia and hyperlipemia have been seen in humans administered temsirolimus.

The primary findings observed in the IV repeat-dose toxicity studies in rats and monkey are provided in the following Table 7.

Table 7: Principal Findings in IV Repeat-Dose Toxicity Studies in Rats and Monkeys

Type of Study	Species/ Strain; N	Route; Duration	Dosage (mg/kg)	Principal Effects Observed
Once-Daily Dosing	Rats/S-D; 5/sex/dosage	Intravenous; 2 Weeks	0 0.1 0.25 1 2.5	<ul style="list-style-type: none"> No mortality and no temsirolimus-related clinical observations. Final body weights decreased at all dosages (4% to 24%). Food consumption slightly decreased at all dosages. Decreased WBCs at ≥ 1 mg/kg, primarily related to decreased lymphocytes. Decreased platelets at all dosages. Increased neutrophils at ≥ 1 mg/kg, and increased fibrinogen at all dosages. Increased glucose at ≥ 0.25 mg/kg, increased cholesterol at ≥ 0.1 mg/kg, decreased albumin at ≥ 0.25 mg/kg, and increased globulin at ≥ 1 mg/kg. Thymus weights decreased at ≥ 0.1 mg/kg; correlated with small thymuses and thymic atrophy at ≥ 0.1 mg/kg. Bone marrow hypocellularity at ≥ 0.25 mg/kg.^a Testes weights decreased at ≥ 1 mg/kg; correlated with slight to moderate tubular degeneration at 2.5 mg/kg. Slight to mild epithelial atrophy of prostate at ≥ 0.1 mg/kg and atrophy of seminal vesicles at ≥ 0.25 mg/kg. Fracture of the callus in the proximal tibia of 2 males at 2.5 mg/kg.^b Slight to mild pancreatic islet cell vacuolation at ≥ 0.25 mg/kg.^c Increased incidence and/or severity of hepatocellular vacuolation at ≥ 0.1 mg/kg and renal tubular vacuolar degeneration at ≥ 0.25 mg/kg. Increased incidence and severity of myocardial degeneration at ≥ 0.1 mg/kg.^d Increased numbers of pulmonary alveolar macrophages, perivascularitis, and pulmonary inflammation characterized by thickened alveolar septae and alveoli containing a few inflammatory cells at ≥ 0.1 mg/kg.^c With the exception of bone fractures, the changes for clinical pathology, organ weight, and macroscopic and microscopic findings not considered dose limiting or adverse. Bone fractures is considered adverse due to the nature of the finding. NOAEL not determined.
Cyclic (Cycles of 5 days of once- daily dosing separated by 9 days without dosing)	Rats/S-D; 15/sex/dosage	Intravenous; 4 Cycles	0 0.1 0.5 2.5	<ul style="list-style-type: none"> No temsirolimus-related mortality. Lameness in 1 male at 2.5 mg/kg.^b Fractures not observed on macroscopic or microscopic examinations. Body weights decreased (4% to 19%) at ≥ 0.5 mg/kg, with slightly decreased food consumption. More pronounced in weeks with dosing than weeks without dosing. Anterior suture or cortical cataracts observed at 2.5 mg/kg.^c During weeks with dosing, platelet and WBC (lymphocytes, monocytes, eosinophils, and basophils) counts decreased at all dosages; reversed during the first non-dosing week and were either similar to or greater than controls. Neutrophils increased at ≥ 0.5 mg/kg and fibrinogen increased at all dosages. Glucose and cholesterol increased at ≥ 0.1 mg/kg. Albumin decreased at ≥ 0.1 mg/kg, and globulin increased at 2.5 mg/kg.

Table 7: Principal Findings in IV Repeat-Dose Toxicity Studies in Rats and Monkeys (Cont'd)

Type of Study	Species/ Strain; N	Route; Duration	Dosage (mg/kg)	Principal Effects Observed
				<ul style="list-style-type: none"> • Testes weights decreased at 2.5 mg/kg; correlated with small testes and slight to severe testicular tubular degeneration and tubular giant cells. Small seminal vesicles, prostates, and epididymides observed at 2.5 mg/kg; correlated with mild prostate atrophy and slight to marked hypospermia and/or slight immature spermatozoa in the epididymides. In most cases, testicular tubular degeneration considered reversible because normal appearing Sertoli and germinal cells were present. In instances of severe degeneration in which tubules were lined only by Sertoli cells, degeneration may not have been reversible and was considered adverse. • Ovary weights decreased at ≥ 0.1 mg/kg. Not considered adverse due to low magnitude of change and absence of macroscopic or microscopic correlates. • Increased incidences of slight lymphoid atrophy of the cervical and/or mesenteric lymph nodes and slight to mild thymic atrophy observed at ≥ 0.1 mg/kg. Not considered adverse due to slight to mild severity. • Increased numbers of pulmonary alveolar macrophages (slight to mild) and myocardial degeneration (slight to moderate) in all temsirolimus-dosed groups.^{d, e} • Slight to moderate hepatocellular vacuolation occurred with increased incidence and severity at ≥ 0.1 mg/kg. • Increased incidence of panniculitis at injection site at ≥ 0.1 mg/kg; severity slight and not considered adverse. • NOAEL: 0.5 mg/kg. AUC₀₋₂₄ at the NOAEL dosage: M - 650 ng•h/mL, F - 460 ng•h/mL.
Once-Weekly Dosing	Rats/S-D; 15/sex/dosage (recovery 10/sex at 0 and 2.5)	Intravenous; 6 months (3-month recovery)	0 0.1 0.5 2.5	<ul style="list-style-type: none"> • One animal in each of the 0.5 mg/kg/week and 2.5 mg/kg/week groups died of lower urinary tract disease. These deaths were not considered related to treatment with temsirolimus. • Body weights decreased at all dosages. At the end of dosing, 7% to 29% at end of recovery 24% (2.5 mg/kg). Decreases at ≥ 0.5 mg/kg considered adverse due to magnitude of the change. Food consumption decreased at ≥ 0.5 mg/kg during dosing and at 2.5 mg/kg during recovery. • At week 12, early cortical cataracts (anterior suture cataracts, incipient anterior cortical opacities, and/or posterior polar cataracts) observed at 2.5 mg/kg in 13 of 25 M and 1 of 25 F. ^c At week 25, severity and incidence of cataracts increased (observed at 0.5 mg/kg in 3 of 14 M and at 2.5 mg/kg in 16 of 24 M and 2 of 25 F). At the end of recovery, cataracts still present in affected animals, but no new cataract formation observed. Ocular opacities observed as clinical observations and slight or moderate cataracts observed microscopically at the end of dosing in males at 0.5 or 2.5 mg/kg. • Decreased lymphocytes at 2.5 mg/kg correlated with lymphoid atrophy. Increased neutrophils and fibrinogen at ≥ 0.1 mg/kg. • Increased cholesterol and decreased triglycerides at ≥ 0.1 mg/kg; increased glucose at ≥ 0.5 mg/kg; and decreased total protein (primarily albumin) at ≥ 0.5 mg/kg; and decreased globulin at 2.5 mg/kg. • Pituitary weights decreased at the end of dosing at ≥ 0.1 mg/kg. Pituitary weights were similar to controls at the end of recovery. No macroscopic or microscopic findings.

Table 7: Principal Findings in IV Repeat-Dose Toxicity Studies in Rats and Monkeys (Cont'd)

Type of Study	Species/ Strain; N	Route; Duration	Dosage (mg/kg)	Principal Effects Observed
				<ul style="list-style-type: none"> • Testes weights decreased at 2.5 mg/kg at the end of dosing and at end of recovery. Correlated with small testes and testicular tubular degeneration at the end of dosing (slight to marked severity) and recovery (moderate to marked severity). Tubular degeneration considered adverse at 2.5 mg/kg due to severity of the lesions at the end of dosing and recovery. Decreased prostate weights correlating with slight to mild prostate atrophy, mild to moderate epididymal luminal cellular debris, and slight to marked hypospermia at ≥ 0.5 mg/kg at the end of dosing and in recovery animals; and slight to mild decreased seminal vesicle content at ≥ 0.1 mg/kg at the end of dosing, but not in recovery animals. Prostate changes not considered adverse; considered secondary to tubular degeneration. • Uterine atrophy at the end of dosing at all dosages; not seen in recovery animals. Ovarian follicular cysts not observed at end of dosing, but seen in 4 of 10 recovery animals. Uterine atrophy may have been related in part to decreased body weight, and neither uterine atrophy nor ovarian follicular cysts considered adverse due to low severity. • Thymus weights decreased at ≥ 0.5 mg/kg at the end of dosing and at recovery (2.5 mg/kg); correlated with small thymuses at 0.1 and 2.5 mg/kg and slight to moderate thymic atrophy at ≥ 0.5 mg/kg at the end of dosing. Increased incidences of slight to moderate lymphoid atrophy in GALT and mesenteric lymph nodes at ≥ 0.1 mg/kg and in mandibular lymph nodes at ≥ 0.5 mg/kg. Increased incidence of bone marrow hypocellularity in males at ≥ 0.5 mg/kg.^a Lymphoid atrophy and bone marrow hypocellularity not observed in recovery animals. Pigmented macrophage infiltrate in mesenteric lymph node observed at the end of dosing in treated animals and at the end of the recovery period in controls and treated animals; not considered adverse because it was not accompanied by degenerative changes and, at recovery, was present at similar incidence and severity in control females and in temsirolimus-dosed females. • Spleen weights decreased in males at ≥ 0.1 mg/kg at the end of dosing and in recovery animals. Increased incidences of hemosiderosis at ≥ 0.1 mg/kg at the end of dosing and in recovery animals and may represent increased RBC turnover. Changes in spleen not adverse due to low magnitude of weight changes and low severity of the lesions. • Heart weights decreased at ≥ 0.5 mg/kg at the end of dosing and in recovery animals. Increased incidence of myocardial degeneration at ≥ 0.1 mg/kg at the end of dosing, but not in recovery animals.^d • Liver weights decreased at 2.5 mg/kg at the end of dosing and in recovery animals. Slight to mild necrosis at ≥ 0.1 mg/kg at the end of dosing, but not in recovery animals.^f Increased incidence of mononuclear cell inflammation in treated groups at the end of dosing and recovery. Not considered adverse due to low incidence and severity. • Increased incidences of pulmonary alveolar macrophages at ≥ 0.1 mg/kg at the end of dosing (slight to marked severity) and recovery (slight to mild severity).^c • NOAEL: 0.1 mg/kg. AUC₀₋₁₆₈ at the NOAEL: M - 591 ng•h/mL, F - 328 ng•h/mL.
Once-Daily Dosing	Monkeys/ Cynomolgus; 1/sex/dosage	Intravenous; 2 Weeks	0 0.1 0.25 1 2.5	<ul style="list-style-type: none"> • No mortality and no temsirolimus-related effects on food consumption or clinical chemistry. • Diarrhea and/or loose stools in several monkeys throughout the study, including a control animal; however, time of onset (week 2) at 2.5 mg/kg indicated the diarrhea may have been temsirolimus related in these animals. • Body weight decreased compared with pre-test weight at ≥ 1 mg/kg (9% -11%).

Table 7: Principal Findings in IV Repeat-Dose Toxicity Studies in Rats and Monkeys (Cont'd)

Type of Study	Species/ Strain; N	Route; Duration	Dosage (mg/kg)	Principal Effects Observed
				<ul style="list-style-type: none"> Lymphocytes decreased compared with pre-test values in all monkeys, including controls; magnitude of change greater at 2.5 mg/kg than in controls. Fibrinogen increased in all study animals, including controls; magnitude of change greater at ≥ 0.25 mg/kg than in controls. Small, normal-appearing, immature testes in the male given 1 mg/kg; due to the small sample size, a temsirolimus-related effect on the testes could not be excluded. Lymphoid atrophy of the cervical and/or mesenteric lymph nodes (slight to mild) and thymus (slight to marked) at ≥ 0.1 mg/kg. Inflammation of the crypts in the cecum and colon in 2 monkeys (control and 0.25 mg/kg), with the severity being greater at 0.25 mg/kg. NOAEL: 0.1 mg/kg.
Cyclic (Cycles of 5 days of once-daily dosing separated by 9 days without dosing)	Monkeys/ Cynomolgus; 3/sex/dosage	Intravenous; 4 Cycles	0 0.1 0.5 2.5	<ul style="list-style-type: none"> No mortality and no temsirolimus-related effects on body weight, food consumption, ophthalmoscopy, or urine parameters. Diarrhea and/or loose stools at ≥ 0.1 mg/kg. Lymphocytes decreased relative to pretest values at ≥ 0.5 mg/kg. Evidence of recovery following the first interval without dosing, as indicated by a smaller decrease in lymphocytes in these animals. Fibrinogen increased at ≥ 0.1 mg/kg. Platelets increased at ≥ 0.5 mg/kg. PT increased (1 second) at 2.5 mg/kg, and APTT increased (1 to 3 seconds) at ≥ 0.1 mg/kg. Changes in clinical pathology not adverse due to small magnitude of change. Globulin increased (compared with individual animal pretest values) at ≥ 0.5 mg/kg. Decreased testes weights at ≥ 0.1 mg/kg; correlated with mild to marked testicular tubular degeneration and hypospermia at ≥ 0.5 mg/kg. Tubular giant cells in 1 male at 0.5 mg/kg. Tubular degeneration not considered adverse; the change considered reversible based on normal appearing Sertoli cells and the presence of germinal cells. Small thymuses at ≥ 0.1 mg/kg. Slight to mild lymphoid atrophy of the thymus and cervical and/or mesenteric lymph nodes at all dosages, and slight to moderate lymphoid atrophy of the spleen at ≥ 0.5 mg/kg. Inflammation of the cecum at 2.5 mg/kg and consisted of focal neutrophilic infiltration of the mucosa. Not adverse due to focal distribution of the lesion and low severity. NOAEL: 2.5 mg/kg. AUC₀₋₂₄ at the NOAEL: 3448 ng•h/mL.
Once-Weekly Dosing	Monkeys/ Cynomolgus; 4/sex/dosage (recovery 3/sex at 2.5)	Intravenous; 9 Months (3 month recovery)	0 0.1 0.5 2.5	<ul style="list-style-type: none"> Two (2) females (at 0.1 and 2.5 mg/kg) euthanized due to temsirolimus-related observations of thin appearance and chronic fecal alterations. Temsirolimus-related findings were lymphoid atrophy in thymus, mesenteric lymph node, and GALT in the 2.5 mg/kg female and erosions, cysts, or mixed cell inflammation in cecal or colonic mucosa, and lymphoid atrophy in thymus and mandibular lymph node in the 0.1 mg/kg female. Increased incidence of fecal alterations at ≥ 0.1 mg/kg and increased persistence and extent of rashes at ≥ 0.5 mg/kg. Fecal alterations adverse at ≥ 0.5 mg/kg. Increased rashes secondary to chronic antiproliferative effects and not a direct toxic effect. Body-weight gains during dosing decreased in males at ≥ 0.5 mg/kg (47% to 53%) and females at 2.5 mg/kg lost 0.07 kg compared with a gain of 0.33 kg in female controls. Food consumption decreased at 2.5 mg/kg. However, no consistent changes in body weights, and effects on body-weight gain and food consumption not adverse and resolved by end of recovery. Increased neutrophils and fibrinogen. At ≥ 0.1 mg/kg, increased cholesterol. All clinical pathology changes partially to completely resolved by the end of recovery. There were no temsirolimus-related ophthalmoscopy or urinalysis findings.

Table 7: Principal Findings in IV Repeat-Dose Toxicity Studies in Rats and Monkeys (Cont'd)

Type of Study	Species/ Strain; N	Route; Duration	Dosage (mg/kg)	Principal Effects Observed
				<ul style="list-style-type: none"> • Testes weights decreased at ≥ 0.5 mg/kg; correlated with small testes and mild testicular tubular degeneration in 1 male at 2.5 mg/kg. Not adverse due to mild severity and recoverability of the lesion. Not seen at recovery. • Increased incidence of lymphoid atrophy in the thymus (slight to marked severity), GALT, and the mandibular and mesenteric lymph nodes (slight or mild severity) primarily at ≥ 0.5 mg/kg. Not observed at recovery. • Adrenal weights increased at ≥ 0.1 mg/kg. No macroscopic or microscopic findings; not considered adverse. Adrenal weights partially to completely reversible at recovery. • NOAEL not determined.
a.				Bone marrow hypocellularity, observed in rats, may have been due to an antiproliferative effect on the lymphoid elements in bone marrow. Lymphoid elements are present at higher levels in rat bone marrow than in bone marrow from other species.
b.				Lameness, with or without evidence of bone fracture, observed in rats administered sirolimus (a similar compound) was associated with decreased testosterone levels.
c.				Hyperglycemia and pancreatic islet cell vacuolation were observed in rats and were considered to be associated with cataracts, hepatocellular vacuolation, and renal tubular vacuolation in some studies.
d.				Increased incidence and severity of myocardial degeneration (sometimes described as spontaneous rat cardiomyopathy) was an exacerbation of a naturally occurring condition in rats and may not be relevant to humans.
e.				Increased numbers of pulmonary alveolar macrophages were seen in rats without appreciable inflammatory change and were consistent with phospholipidosis. Accumulation of phospholipid in rat pulmonary alveolar macrophages is associated with a variety of different compounds and is not generally predictive of adverse findings in humans.
f.				Focal inflammatory hepatocellular lesions can be an incidental finding, but can also occur as a treatment effect related to increased numbers of bacteria in the enterohepatic circulation.

APTT = Activated partial thromboplastin time; AUC = Area under the concentration-versus-time curve; GALT = Gastrointestinal-associated lymphoid tissue; N = Number of animals; NOAEL = No-observed-adverse-effect level; PT = Prothrombin time; RBC = Red blood cell; S-D = Sprague-Dawley; WBC = White blood cell.

Carcinogenicity

Carcinogenicity studies have not been conducted with temsirolimus.

Genotoxicity

Temsirolimus was not genotoxic in a battery of *in vitro* (bacterial reverse mutation in *Salmonella typhimurium* and *Escherichia coli*, forward mutation in mouse lymphoma cells, and chromosome aberrations in Chinese hamster ovary cells) and *in vivo* (mouse micronucleus) assays. Sirolimus, the main metabolite in humans, was previously shown to be devoid of genotoxicity potential in the same test-battery.

Reproductive and Developmental Toxicity

Studies in animals have shown reproductive toxicity. There are no adequate and well-controlled studies in pregnant women. TORISEL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The effects of temsirolimus on fertility was not evaluated with the intravenous route of administration, but only in oral studies in male and female rats. The bioavailability of temsirolimus administered orally is limited; the maximal dose used in these studies did not

produce the levels of temsirolimus exposure corresponding to the clinical exposure in humans. Therefore, the effects of temsirolimus at clinically relevant exposure have not been evaluated. Nevertheless, oral studies demonstrated that in male rats, fertility was decreased at ≥ 0.5 mg/kg. Fertility was absent at 5 mg/kg. These effects on male fertility were accompanied by testicular tubular degeneration, decreased sperm concentration and motility, and decreased reproductive organ weights at oral dosages ≥ 0.5 mg/kg.

In fertility studies in female rats, there were increased incidences of pre and post-implantation losses at oral dosages ≥ 0.7 mg/kg, resulting in decreased numbers of live fetuses. Fetal weights were decreased at dosages ≥ 1 mg/kg.

In oral developmental toxicity studies in rats, there were increased embryo/fetal mortality and decreased fetal growth at dosages > 0.45 mg/kg.

In oral developmental toxicity studies in rabbits, there were increased embryo/fetal mortality and decreased fetal growth at dosages ≥ 0.6 mg/kg. Additionally in rabbits, there was an increased incidence of intestinal protrusion through the abdomen at 0.9 mg/kg.

REFERENCES

- 1 Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eu J Cancer* 2006;42:1875-1880.
- 2 Bjornsti M-A, Houghton PJ. The TOR pathway: A target for cancer therapy. *Nature Reviews-Cancer*. 2004;4:335-348.
- 3 Abraham RT. MTOR as a positive regulator of tumor cell responses to hypoxia. *Current Topics in Microbiol Immunol* 2004;279:299-319.
- 4 Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. *Proceed Nat Acad Sciences USA*. 1990;87(23):9231-9235.
- 5 Gelber RD and Goldhirsh A: A new endpoint for the assessment of adjuvant therapy on postmenopausal women with operable breast cancer. *J. Clin. Oncol*. 1986;4:1772-1779.
- 6 Cole BF, Bonetti M, Zaslavsky AM, Gelber RD. A multi-state Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. *Statistics in Med* 2005;24(15):2317-2334.
- 7 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2007;356:2271-81.
- 8 Dutcher JP, de Souza P, McDermott D, Figlin R, Berkenblit A et al. Effect of temsirolimus versus interferon- α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. *Med Oncol* (2009) 26:202–209.

PART III: CONSUMER INFORMATION

Pr TORISEL™

Temsirolimus Concentrate for Injection, 25mg/mL

This leaflet is part III of a three-part "Product Monograph" published when TORISEL was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TORISEL. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

TORISEL is used in the treatment of metastatic cancer of the kidney (when cancer cells have spread from kidney to other parts of the body).

What it does:

TORISEL is a selective inhibitor of mTOR (mammalian target of rapamycin) that blocks tumour cell growth and division.

When it should not be used:

Do not take TORISEL if you;

- are allergic (hypersensitive) to temsirolimus, sirolimus or any of the other ingredients of TORISEL
- have moderate or severe liver problems

What the medicinal ingredient is:

Temsirolimus

What the important nonmedicinal ingredients are:

TORISEL: dehydrated alcohol, *d,l*-alpha-tocopherol, propylene glycol, citric acid anhydrous.

DILUENT for TORISEL: polysorbate 80, polyethylene glycol 400, dehydrated alcohol.

What dosage forms it comes in:

Concentrate for injection. Each mL contains 25 mg temsirolimus.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

TORISEL should be prescribed and managed by a doctor who is experienced in the use of anti-cancer drugs.

Possible serious side-effects with TORISEL include:

- Allergic (hypersensitivity/infusion) reactions
- Increased blood glucose levels
- Increased susceptibility to infections

- Chronic inflammation of the lungs (interstitial lung disease)
- Kidney failure

BEFORE you use TORISEL talk to your doctor or pharmacist if:

- You are allergic (hypersensitive) to antihistamines or cannot take antihistamines for other medical reasons.
- You are allergic (hypersensitive) to sirolimus (used to prevent the body from rejecting transplanted kidneys).
- You have diabetes or you experience any excessive thirst or increased frequency of urination. TORISEL may increase blood glucose levels. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycaemic agent therapy.
- You have problems with your heart.
- You have QT prolongation or a family history of QT prolongation.
- You have a personal history of fainting spells.
- You have a family history of sudden cardiac death at <50 years.
- You have electrolyte disturbances (e.g. low blood potassium or magnesium levels) or conditions that could lead to electrolyte disturbances (e.g. vomiting, diarrhea, dehydration).
- You have an eating disorder or are following a strict diet.
- You have had a recent fever, sweats, chills or infection diagnosed. TORISEL may weaken your immune system, therefore, you may be at risk of getting an infection while you are taking TORISEL.
- You experience shortness of breath, cough, and fever or any new or worsening respiratory symptoms.
- You have kidney problems (in addition to kidney cancer)
- You have liver problems.
- You have known or suspected lesions of the gastrointestinal tract. TORISEL may cause bowel perforation. Rare fatal cases have been reported.
- You have high cholesterol. TORISEL may elevate triglycerides and/or cholesterol. This may require treatment with lipid lowering agents.
- You are going to have an operation, if you have had recent major surgery, or if you still have an unhealed wound following surgery, you should tell your doctor before receiving this medicine, as TORISEL may increase the risk of problems with wound healing.
- You are currently taking ACE inhibitors (used to treat high blood pressure and heart failure).
- You are planning to have a vaccination during treatment with TORISEL, the vaccination may be less effective. The use of live vaccines and close contact with people who have received live vaccines should be avoided during treatment with TORISEL.
- You have bleeding problems and/or receiving blood thinners. TORISEL may increase the risk of bleeding and/or bleeding in the brain.
- You are experiencing muscle pain or weakness.

- You are pregnant or are thinking about becoming pregnant. TORISEL may interfere with the growth and development of an unborn baby. You must use reliable methods of birth control during treatment and for 3 months after the last dose of TORISEL.
- You are a male and have a partner of childbearing potential. The affects of TORISEL on the fetus and sperm are unknown. You must use reliable methods of birth control during treatment and for 3 months after the last dose of TORISEL.
- You are breastfeeding during treatment with TORISEL. Women should not breast-feed during treatment, as this medicine may interfere with the growth and development of the baby. It is not known if TORISEL passes into breast milk.

INTERACTIONS WITH THIS MEDICATION

Please tell your doctor if you are taking, or have recently taken, any other medicines including medicines obtained without a prescription.

Some medicines can interfere with the breakdown or metabolism of TORISEL. In particular, you should inform your doctor if you are taking any of the following:

- protease inhibitors (used in the treatment of HIV) such as indinavir, nelfinavir, ritonavir
- macrolide antibiotics (e.g., clarithromycin, erythromycin) or antifungal medicines (e.g., itraconazole, ketoconazole, voriconazole) used to treat infections
- nefazodone or selective serotonin re-uptake inhibitors used to treat depression
- anti-epileptic medicines including carbamazepine, phenytoin and barbiturates
- rifabutin used to treat infection in people with HIV
- rifampicin used to treat infections
- angiotensin converting enzyme (ACE)-inhibitors (such as enalapril, ramipril, lisinopril) or a calcium channel blocker (such as amlodipine) used to treat high blood pressure or other cardiovascular problems
- St. John's Wort (*Hypericum perforatum*)
- drugs that prolong QT/QTc
- medications that can decrease body's natural defence response to infections, such as corticosteroids.

Non-human studies have shown that TORISEL interacts with digoxin (used to treat heart failure)

PROPER USE OF THIS MEDICATION

Usual dose:

TORISEL will always be prepared and given to you by a doctor or another healthcare professional.

The recommended dose of TORISEL is 25 mg infused over a 30 to 60 minute period once weekly. You may be given an antihistamine intravenously (into your vein) before your dose of TORISEL.

Overdose:

In case of drug overdosage, contact a healthcare professional (e.g. doctor), hospital emergency department, or regional poison control centre, even if there are no symptoms.

- Always take the labelled medicine bottle with you, even if it is empty.

Missed dose:

If you are concerned that you may have missed a dose, tell your doctor immediately.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, TORISEL can cause side effects, although not everybody gets them.

Very Common side effects of TORISEL occurring in more than 1 in 10 patients are:

General feeling of weakness, swelling due to fluid retention, pain (including abdominal, back and chest pain), fever, nausea, anorexia, diarrhoea, vomiting, swelling and sores in the mouth and/or digestive tract, cough, low red blood cell count, sore throat, infections, high blood sugar, high cholesterol, joint pain, abscess, urinary tract infections, abnormal kidney function, shortness of breath, nose bleed, runny nose, rash, itching, nail disorder, acne, dry skin, change in the sense of taste, weight loss and sleeplessness.

Common side effects of TORISEL occurring in less than 1 out of 10 patients but more than 1 per 100 patients are:

High blood pressure, stomach bloating, gum inflammation, mouth pain, redness and swelling of the tissues around the eye, blood tests which show changes in the way the liver is working, low levels of phosphate in the blood, low levels of potassium in the blood which may cause muscle weakness, twitching or abnormal heart rhythm, increased blood clotting (including thrombosis of the veins, embolism in the lung), upper respiratory infections, pneumonia, interstitial lung disease (inflammation or infection of the lungs), allergic (hypersensitivity) reactions, taste loss, inflammation of the follicles in the skin, decreased number of white blood cells, decreased number of lymphocytes and problems with healing after surgery.

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
	Only if severe	In all cases	
Very Common			
Excessive thirst or frequency of urination suggestive of increased blood glucose levels		✓	
Any fever, sweats or chills, or other symptoms suggestive of an infection		✓	
Elevated triglycerides and/or cholesterol that may require treatment with lipid lowering agents		✓	
Common			
Swelling or difficulty breathing suggestive of an allergic (hypersensitivity/infusion) reaction			✓
Shortness of breath, cough, and fever suggestive of inflammation or infection of the lungs		✓	
Uncommon			
Decreased urine production, body swelling, fatigue, abdominal pain suggestive of kidney failure		✓	
Stomach pain, nausea, or blood in the stool suggestive of lesions in the gastrointestinal tract (bowel perforation)		✓	

This is not a complete list of side effects. For any unexpected effects while taking TORISEL, contact your doctor or pharmacist.

HOW TO STORE IT

Keep out of reach and sight of children.

Store in a refrigerator (2°C to 8°C).

Keep the vial in the outer carton in order to protect from light.

Do not use this medicine after the expiry date stated on the container.

Infusion solutions should be used up to 6 hours after dilution, and any unused medicine should be discarded.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701D
Ottawa, Ontario
K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at <http://www.pfizer.ca> or by contacting the sponsor, Pfizer Canada, at: 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last revised: 21 December 2016

L4-Notification: 10 May 2021